Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06486181 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Second Line Endovascular Treatment in Acute DVT

StatusNot Yet Recruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Start date: Dec 1, 2025 to Apr 1, 2026
    • Primary completion date: Dec 30, 2027 to Apr 30, 2028
    • Study completion date: Dec 30, 2028 to Apr 30, 2029
    v6
  2. Primary completion date: Aug 30, 2026 to Dec 30, 2027
    • Start date: Aug 1, 2025 to Dec 1, 2025
    • Study completion date: Aug 30, 2027 to Dec 30, 2028
    v5
  3. Start date: Apr 1, 2025 to Aug 1, 2025
    • Primary completion date: Jun 30, 2026 to Aug 30, 2026
    • Study completion date: Jun 30, 2027 to Aug 30, 2027
    • Site contact updated
    v4
  4. Phase: Not applicable to Phase 4v3 Show 4 more changesShow less
    • Primary completion date: Jun 30, 2025 to Jun 30, 2026
    • Start date: Oct 1, 2024 to Apr 1, 2025
    • Study completion date: Jun 30, 2026 to Jun 30, 2027
    • Site contact updated
  5. Start date: Jul 1, 2024 to Oct 1, 2024v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this study is to fill the paucity of second line endovascular treatment for acute deep venous thrombus (DVT) by using catheter-directed thrombolysis (CDT) and mechanical thrombectomy (MT) as adjunctive second-line treatments for acute DVT patients who show no improvement after an initial anticoagulation trial for one week. The main questions the study aims to answer are: \- Are adjunctive use of endovascular interventional treatments as second-line to DVT treatment safe and efficient? Participants will be followed with repeat US at 1 week after initial DVT to assess for response to anticoagulation treatment. If there is significant residual thrombus with minimal or no response to treatment, participants will be offered enrollment to the study in the office or inpatient setting. Enrolled participants will be randomized into control or intervention arms with 1:1 ratio. Researchers will compare follow-up Villalta and Marder scores between groups to see whether endovascular interventions are safe and efficient.
Trial Details
NCT Number NCT06486181
Lead Sponsor Rush University Medical Center
Conditions
(from sponsor)		 Deep Venous Thrombosis
Related terms Venous Thrombosis
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov